BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31551362)

  • 1. Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma.
    Sato T; Yoo S; Kong R; Sinha A; Chandramani-Shivalingappa P; Patel A; Fridrikh M; Nagano O; Masuko T; Beasley MB; Powell CA; Zhu J; Watanabe H
    Cancer Res; 2019 Dec; 79(24):6084-6100. PubMed ID: 31551362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression.
    Jiang Y; Jiang YY; Xie JJ; Mayakonda A; Hazawa M; Chen L; Xiao JF; Li CQ; Huang ML; Ding LW; Sun QY; Xu L; Kanojia D; Jeitany M; Deng JW; Liao LD; Soukiasian HJ; Berman BP; Hao JJ; Xu LY; Li EM; Wang MR; Bi XG; Lin DC; Koeffler HP
    Nat Commun; 2018 Sep; 9(1):3619. PubMed ID: 30190462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAK5 promotes the cell stemness ability by phosphorylating SOX2 in lung squamous cell carcinomas.
    Bao Z; Ji W; Yang Y; Chen Z; Li Z; Wang K; Lu T; Yu Y; Xia W; Lu S
    Exp Cell Res; 2020 Oct; 395(2):112187. PubMed ID: 32721391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture.
    Chen S; Giannakou A; Wyman S; Gruzas J; Golas J; Zhong W; Loreth C; Sridharan L; Yamin TT; Damelin M; Geles KG
    Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11671-E11680. PubMed ID: 30487219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma.
    Lazarus KA; Hadi F; Zambon E; Bach K; Santolla MF; Watson JK; Correia LL; Das M; Ugur R; Pensa S; Becker L; Campos LS; Ladds G; Liu P; Evan GI; McCaughan FM; Le Quesne J; Lee JH; Calado D; Khaled WT
    Nat Commun; 2018 Aug; 9(1):3327. PubMed ID: 30127402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural lineage-specific homeoprotein BRN2 is directly involved in TTF1 expression in small-cell lung cancer.
    Sakaeda M; Sato H; Ishii J; Miyata C; Kamma H; Shishido-Hara Y; Shimoyamada H; Fujiwara M; Endo T; Tanaka R; Kondo H; Goya T; Aoki I; Yazawa T
    Lab Invest; 2013 Apr; 93(4):408-21. PubMed ID: 23358112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOX2 co-occupies distal enhancer elements with distinct POU factors in ESCs and NPCs to specify cell state.
    Lodato MA; Ng CW; Wamstad JA; Cheng AW; Thai KK; Fraenkel E; Jaenisch R; Boyer LA
    PLoS Genet; 2013; 9(2):e1003288. PubMed ID: 23437007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung.
    Yuan P; Kadara H; Behrens C; Tang X; Woods D; Solis LM; Huang J; Spinola M; Dong W; Yin G; Fujimoto J; Kim E; Xie Y; Girard L; Moran C; Hong WK; Minna JD; Wistuba II
    PLoS One; 2010 Feb; 5(2):e9112. PubMed ID: 20161759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas.
    Watanabe H; Ma Q; Peng S; Adelmant G; Swain D; Song W; Fox C; Francis JM; Pedamallu CS; DeLuca DS; Brooks AN; Wang S; Que J; Rustgi AK; Wong KK; Ligon KL; Liu XS; Marto JA; Meyerson M; Bass AJ
    J Clin Invest; 2014 Apr; 124(4):1636-45. PubMed ID: 24590290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-restricted circular RNA circSOX2 suppressed the malignant progression in SOX2-amplified LUSC.
    Liang Y; Wang N; Zhang Y; Jiang W; Fang C; Feng Y; Ma H; Jiang F; Dong G
    Cell Death Dis; 2022 Oct; 13(10):873. PubMed ID: 36243874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
    Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
    Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landscape of transcriptional deregulation in lung cancer.
    Zhang S; Li M; Ji H; Fang Z
    BMC Genomics; 2018 Jun; 19(1):435. PubMed ID: 29866045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment.
    Mollaoglu G; Jones A; Wait SJ; Mukhopadhyay A; Jeong S; Arya R; Camolotto SA; Mosbruger TL; Stubben CJ; Conley CJ; Bhutkar A; Vahrenkamp JM; Berrett KC; Cessna MH; Lane TE; Witt BL; Salama ME; Gertz J; Jones KB; Snyder EL; Oliver TG
    Immunity; 2018 Oct; 49(4):764-779.e9. PubMed ID: 30332632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma.
    Fang WT; Fan CC; Li SM; Jang TH; Lin HP; Shih NY; Chen CH; Wang TY; Huang SF; Lee AY; Liu YL; Tsai FY; Huang CT; Yang SJ; Yen LJ; Chuu CP; Chen CY; Hsiung CA; Chang JY; Wang LH; Chang IS; Jiang SS
    Int J Cancer; 2014 Aug; 135(4):809-19. PubMed ID: 24477565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-omics analysis at epigenomics and transcriptomics levels reveals prognostic subtypes of lung squamous cell carcinoma.
    Xu Y; She Y; Li Y; Li H; Jia Z; Jiang G; Liang L; Duan L
    Biomed Pharmacother; 2020 May; 125():109859. PubMed ID: 32036209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer.
    Liu Y; Wu Z; Zhou J; Ramadurai DKA; Mortenson KL; Aguilera-Jimenez E; Yan Y; Yang X; Taylor AM; Varley KE; Gertz J; Choi PS; Cherniack AD; Chen X; Bass AJ; Bailey SD; Zhang X
    Nat Commun; 2021 Dec; 12(1):7139. PubMed ID: 34880227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma.
    Liu Y; Yin N; Wang X; Khoor A; Sambandam V; Ghosh AB; Fields ZA; Murray NR; Justilien V; Fields AP
    Cell Rep; 2020 Jan; 30(3):771-782.e6. PubMed ID: 31968252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of downregulated ADARB1 in lung squamous cell carcinoma.
    Wang X; Ren X; Liu W; Chen X; Wei J; Gong Z; Yan Y; Xu Z
    Mol Med Rep; 2020 Mar; 21(3):1517-1526. PubMed ID: 32016472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression, significance and function of cancer susceptibility candidate 9 in lung squamous cell carcinoma: A bioinformatics and in vitro investigation.
    Gao L; Guo YN; Zeng JH; Ma FC; Luo J; Zhu HW; Xia S; Wei KL; Chen G
    Int J Oncol; 2019 May; 54(5):1651-1664. PubMed ID: 30896821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
    Liu Z; Deng M; Wu L; Zhang S
    Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.